GlassScriptPhysician profile
Tamella B Cassis
NPI 1962408088
$8,472.26
in general payments reported to CMS, 2019-2025
38 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $983 · 2021: $1,184 · 2022: $1,111 · 2023: $1,731 · 2024: $1,349 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,012 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,011.64 |
| Education | $213.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,284.12 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $668.48 | 2021-2025 | Tremfya |
| Merz North America, INC. | $641.40 | 2019-2024 | Xeomin |
| Amgen INC. | $619.66 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $593.05 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $449.68 | 2019-2025 | Aklief, Epsolay, Oracea |
| Sun Pharmaceutical Industries INC. | $411.53 | 2019-2025 | Winlevi, Absorica Ld |
| Incyte Corporation | $356.23 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $341.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.66 | 2022-2025 | Spevigo |
| Dermavant Sciences, INC. | $261.84 | 2022-2024 | Vtama |
| Leo Pharma INC. | $241.32 | 2019-2023 | Adbry |
| Almirall LLC | $217.84 | 2021-2025 | Klisyri, Seysara |
| Lilly USA, LLC | $211.18 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Mayne Pharma Commercial LLC | $193.49 | 2019-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamella Cassis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.